Claims for Patent: 10,603,275

Summary for Patent: 10,603,275

Title:	Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
Abstract:	Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.
Inventor(s):	Mir Imran, Sara Ansaloni, Radhika Korupolu, Joel M. Harris, Mir Hashim
Assignee:	Rani Therapeutics LLC
Application Number:	US16/183,573

Details for Patent 10,603,275

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	RIXUBIS	coagulation factor ix (recombinant)	For Injection	125446	June 26, 2013	10,603,275	2038-11-07

International Patent Family for US Patent 10,603,275

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2019094521
United States of America	2025195419
United States of America	2024226003
United States of America	2024130965